Daré Bioscience receives Nasdaq minimum bid price notice; compliance due March 29, 2027
Daré Bioscience received a Nasdaq letter dated September 28, 2026, stating that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days. The letter has no immediate effect on the stock's listing, but the company has until March 29, 2027 to regain compliance, and failure to do so could lead to delisting proceedings unless it qualifies for an additional compliance period.
Key points
- Nasdaq letter received September 28, 2026 cites the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2)
- Compliance Date is March 29, 2027, a 180-calendar-day initial period
- Regaining compliance requires a closing bid price of at least $1.00 for 10 consecutive business days, unless Nasdaq extends that period
- A reverse stock split may be needed if the company seeks an additional 180-day period; the company states there is no assurance it will regain compliance
The filing
Written by AI on Nov 9, 2026, 10:08 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 02, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.